Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review.
Jinghong DaiYali XiongHui LiYajun QianYing XuQingqing XuXin YanJian TangPublished in: Clinical rheumatology (2020)
Coronavirus disease 2019 (COVID-19) pneumonia, firstly reported in Wuhan, Hubei province, China, has rapidly spread around the world with high mortality rate among critically ill patients. The use of corticosteroids in COVID-19 remains a major controversy. Available evidences are inconclusive. According to WHO guidance, corticosteroids are not recommended to be used unless for another reason. Chinese Thoracic Society (CTS) proposes an expert consensus statement that suggests taking a prudent attitude of corticosteroid usage. In our clinical practice, we do not use corticosteroids routinely; only low-to-moderate doses of corticosteroids were given to several severely ill patients prudently. In this paper, we will present two confirmed severe COVID-19 cases admitted to isolation wards in Optical Valley Campus of Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology. We will discuss questions related to corticosteroids usages.
Keyphrases
- coronavirus disease
- sars cov
- clinical practice
- respiratory syndrome coronavirus
- healthcare
- ejection fraction
- end stage renal disease
- public health
- newly diagnosed
- prognostic factors
- high resolution
- south africa
- spinal cord
- cardiovascular disease
- drug induced
- spinal cord injury
- risk factors
- community acquired pneumonia
- adverse drug
- smoking cessation
- acute respiratory distress syndrome
- replacement therapy